Takeaways: The Canadian approval expands Epkinly into a second major lymphoma indication (after DLBCL), giving AbbVie a bispecific‑based triplet option in relapsed/refractory follicular ly...
Takeaways: Roche Canada’s completion of pCPA negotiations for Perjeta (pertuzumab) in the neoadjuvant setting (with trastuzumab + chemotherapy) for HER2‑positive, locally advanced, inflammatory...
Takeaways: The expanded approval of Lynkuet for AET‑related VMS gives Canadian oncologists and breast cancer patients the first non‑hormonal, evidence‑based option specifically indicated for...
Takeaways: Itovebi’s addition to Québec’s RAMQ list means eligible patients with advanced HR‑positive, HER2‑negative, PIK3CA‑mutated breast cancer can now access a targeted pill that, in the INAVO120 ...
Takeaways: Septa’s acquisition of CeeNU from Bristol Myers Squibb turns it into a supply‑critical oncology player in Canada, securing an essential chemotherapy that has faced...
Takeaways: This approval expands Padcev from later-line urothelial cancer into earlier-stage muscle-invasive bladder cancer, which should broaden Pfizer’s addressable market in Canada and streng...
Takeaways: Shortening Breyanzi’s required stay-near-centre period and driving ban lowers the logistical and financial barriers to CAR T, which should modestly expand the eligible treat...
For decades, the pharmaceutical industry was built around the blockbuster model, developing medicines with broad indications capable of generating billions in annual revenue. These therapies, often de...
For decades, oncology innovation has focused primarily on developing more effective treatments for advanced disease. Today, however, the industry is beginning to shift toward a new frontier: detecting...
